MDR-1 and MRP2 gene polymorphisms in Mexican epileptic pediatric patients with complex partial seizures

David Escalante-Santiago1,2, Iris Angélica Feria-Romero2, Rosa María Ribas-Aparicio1, Dario Rayo-Mares3, Pietro Fagiolo1, Marta Vázquez1, Consuelo Escamilla-Núñez1, Israel Grijalva-Otero2, Miguel Angel López-García2 and Sandra Orozco-Suárez2,*

1 Programa de Biomedicina y Biotecnología Molecular, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Mexico City, Mexico
2 Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
3 Neurología, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
4 Departamento de Ciencias Farmacéuticas de la Facultad de Química, Universidad de la República, Montevideo, Uruguay
5 Instituto Nacional de Salud Publica, Cuernavaca, Mexico

*Correspondence: Sandra Orozco-Suárez, Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS. Av Cuauhtémoc No. 330-4, Col. Doctores, 06720-25, Mexico city, Mexico e-mail: sorozco5@hotmail.com

Although the Pgp efflux transport protein is overexpressed in resected tissue of patients with epilepsy, the presence of polymorphisms in MDR1/ABCB1 and MRP2/ABCC2 in patients with antiepileptic-drugs resistant epilepsy (ADR) is controversial. The aim of this study was to perform an exploratory study to identify nucleotide changes and search new and reported mutations in patients with ADR and patients with good response (CTR) to antiepileptic drugs (AEDs) in a rigorously selected population. We analyzed 22 samples in Material and Methods, from drug-resistant patients with epilepsy and 7 samples from patients with good response to AEDs. Genomic DNA was obtained from leukocytes. Eleven exons in both genes were genotyped. The concentration of drugs in saliva and plasma was determined. The concentration of valproic acid in saliva was lower in ADR than in CTR. In ABCB1, five reported SNPs and five unreported nucleotide changes were identified; rs2229109 (GA) and rs2032582 (AT and AG) were found only in the ADR. Of six SNPs associated with the ABCC2 that were found in the study population, rs3740066 (TT) and 66744T > A (TG) were found only in the ADR. The strongest risk factor in the ABCB1 gene was identified as the TA genotype of rs2032582, whereas for the ABCC2 gene the strongest risk factor was the T allele of rs3740066. The screening of SNPs in ABC1 and ABCC2 indicates that the Mexican patients with epilepsy in this study display frequently reported ABC1 polymorphisms; however, in the study subjects with a higher risk factor for drug resistance, new nucleotide changes were found in the ABCC2 gene. Thus, the population of Mexican patients with AED-resistant epilepsy (ADR) used in this study exhibits genetic variability with respect to those reported in other study populations; however, it is necessary to explore this polymorphism in a larger population of patients with ADR.

Keywords: drug-resistant, epilepsy, ABCB1, ABCC2, Mexican patients, single-nucleotide polymorphisms, anti-epileptic drugs
phenytoin (PHT), and topiramate (TPM) into the brain (6–9). The gene encoding MDR-1 is \textit{ABCB1}, which is located on chromosome 7q21.12 and consists of 209,461 base pairs (bp) and 29 exons (NCBI reference sequence NG_011513.1). The most extensively studied single-nucleotide polymorphisms (SNPs) in the \textit{ABCB1} gene are rs1128503 (C1236T), rs2032582 (G26777T/A), and rs1045642 (C3435T); the latter has received increased attention as a critical variable in resistance to \textit{AEDs} (10–16) MRP2 is another efflux transporter protein present in the BBB. Its gene, \textit{ABCC2}, is located on chromosome 10q24 and contains 69,000 bp representing 33 exons (NG_011798.1). The MRP2 transporter protein recognizes CBZ, LTG, and FBM; its most relevant polymorphisms are rs2273697 (G1249A) and rs3740066 (C3972T). The latter polymorphism reduces the transport of carbamazepine (17–20). The aim of this study was to perform a non-inferential exploratory study to identify reported nucleotide changes and explore new ones in a rigorously selected Mexican population of patients with AED-resistant epilepsy (ADR) and patients with good response to \textit{AEDs} (CTR).

\section*{MATERIALS AND METHODS}

\subsection*{PATIENTS AND SAMPLE COLLECTION}

This project was approved by the National Research Committee of the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS). An observational study with 22 patients with ADR (cases) and 7 patients with good response to \textit{AEDs} (controls) was performed, while avoiding inbreeding between the patient’s biological parents.

The inclusion criteria for ADR were patients with demonstrable epileptic focus through EEG and radiological focal structural lesion to discard and classified as resistant to pharmacological treatment, treated with two or more drugs (Table 1) at appropriate doses, serum levels within therapeutic range for at least 6 months of continuous treatment, and under the supervision of a neurologist pediatrician, with a frequency of three seizures per month, who attend Neurology Service, Hospital of Pediatrics, National Medical Center, Century XXI, who is of Mexican origin like their parents and grandparents, from 1 to 16 years of age, both genders, whereas for asymptomatic control patients was seizure-free for at least 6 months before the study.

Both groups had complex partial seizures, showed similar clinical variables, were previously selected under medical supervision, and gave written informed consent. Exclusion criteria were all types of seizures that are not complex partial, little adherence to treatment.

A total of 15 ml of blood was collected from each patient via antecubital vein using an EDTA tube, and two fractions of 0.5–2.0 ml of saliva were collected upon stimulation with citric acid. Samples that were used to monitor drug concentrations were taken before the first dose in the morning.

\subsection*{AMPLIFICATION AND SEQUENCING}

Genomic DNA was extracted from leukocytes in patient blood samples using a commercial kit (Genomic DNA Purification kit, Thermo Scientific®, USA), according to the supplier’s recommendations. The polymorphisms (SNPs) from exons 1 (rs9282564), 10 (rs2229109), 11 (rs1128503), 13 (rs28381902), 20 (rs2032582), and 25 (rs1045642) were located in GenBank accession CCDS5608.1, corresponding to the \textit{ABCB1} gene, and exons 10 (rs2273697), 25 (rs8178692, rs17222723), 28 (rs3740066), 29 (rs7899457), and 32 (rs8177710) were located in GenBank accession CCDS7484.1, corresponding to the \textit{ABCC2} gene. These polymorphisms were selected based on their frequency in the Hispanic or Mexican population, as noted in NCBI GenBank. Each amplification reaction was performed with 5 µl (5 ng/µl) of genomic DNA in a 50 µl total reaction volume containing 5 µl of 10× reaction buffer, MgCl$_2$ (concentration depending on the primer set), 1 µl 10 mM dNTPs.

\section*{Table 1 | Demographics and clinical data of patients with AEDs-resistant epilepsy and patients with good response to AEDs}

| Clinical data         | ADR (mean ± SD) | CTR (mean ± SD) |
|-----------------------|-----------------|-----------------|
| Age (years ± SD) range| 10.45 ± 3.762 (1–15) | 11.50 ± 3.017 (1–15) |
| Gender (F/M)          | 12/8            | 3/3             |
| Onset of seizures     | 4.715 ± 3.835 (1–14) | 4.833 ± 3.656 (2–10) |
| Number of seizures/month | 63.45 ± 27.76 (3–450) | – |
| Years of seizures     | 5.85 ± 0.8438 (1–12) | – |
| Controlled time (years ± SD) range | – | 1.9 ± 0.28 (0.6–2) |
| Valproic Ac. dose (mg/day) | 598.0 ± 129.7 | 814.3 ± 212.1 |
| Valproic Ac. concentration/saliva (mg/l) | 0.57 ± 0.12 | 1.68 ± 0.59 |
| Valproic Ac. concentration/plasma (mg/l) | 31.62 ± 8.03 | 35.17 ± 18.04 |
| Carbamazepine dose (mg/day) | 900.0 ± 100.0 | 600.0 ± 200.0 |
| Carbamazepine concentration/saliva (mg/l) | 0.7244 ± 0.3232 | 1.017 ± 0.034 |
| Carbamazepine concentration/plasma (mg/l) | 5.900 ± 0.156 | 6.76 ± 0.29 |
| Phenytoin dose (mg/day) | 145.0 ± 55.00 | 0.9337 ± 0.06814 |
| Phenytoin concentration/saliva (mg/l) | 3.150 ± 1.750 | – |
| Phenytoin concentration/plasma (mg/l) | 1250 ± 322.7 | 1000 ± 0.0 |
| Levetiracetam concentration/saliva (mg/l) | 1.661 ± 0.8825 | – |
| Levetiracetam concentration/plasma (mg/l) | 4.657 ± 0.5897 | – |

$F$, female; $M$, male.
(Thermo Scientific®, USA), 1 µl of each 10 mM flanking primer (Invitrogen®, USA), and 1 µl of Taq polymerase (Thermo Scientific®, USA). PCR was performed in a DNA engine system®thermocycler (Bio-Rad®, USA) with a cycle program at 94°C for 3 min, 38 cycles of 94°C for 30 s, Tm for 35 s for 35 s, and one extension cycle of 10 min at 72°C. The primers, MgCl₂ concentration, and Tm for each amplification reaction are listed in Table 2.

The amplification products were purified with the GeneJET Gel Extraction kit (Thermo Scientific®, USA) and sequenced in a 5 µl total reaction volume using 100 ng of amplicon, Fw or Rv primer, and Big Dye 3.1 sequencing Ready Reaction Kit (Applied Biosystems, USA) according to the manufacturer’s recommendations. Sequencing was performed in a DNA engine system®thermocycler (Bio-Rad®, USA) with a cycle program at 94°C for 1 min, 30 cycles of 94°C for 10 s, 50°C for 5 s, 60°C for 4 min, and finally the fragments were analyzed in Automated Sequencing ABI Prism 310 Gene Analyzer (Applied Biosystems, USA), previous purification with DyeEx 2.0 Spin Kit (Qiagen, Germany).

DRUG MONITORING

Saliva samples were used for VPA and CBZ detection by immunofluorescence with a polarized light system (FPIA, Dade Behring, USA), according to the supplier’s recommendations.

Saliva samples were used to detection concentration of CBZ and PHT (determined by Axsym®, Abbot Laboratories®, USA) according to the supplier’s recommendations, VPA, and LEV [determined by high performance liquid chromatography (HPLC)]. For VPA, 30 µl of an internal standard solution (98% octanoic acid diluted 1/500 with methanol), 200 µl of phosphoric acid, and 5 ml of cyclohexane were added to 1 ml of saliva and vortexed for 2 min. After centrifugation, a back-extraction was performed by adding 100 µl of 1% TEA to the organic phase supernatant. The mixture was vortexed and centrifuged. Finally, 20 µl of the aqueous phase was directly injected into a Dionex Ultimate 3000 Series. A Phenomenex Luna 5 µm CN column (15 cm × 4.6 mm) was used as the stationary phase. The mobile phase was a mixture of 40 mM phosphate potassium, monobasic, pH 3.4: Acetonitrile (90:10). The column compartment was kept at 40°C, and the wavelength of detection was 210 nm. For LEV, 50 µl of internal standard solution (diethylbarbituric acid, 12 mg/l) was added to 500 µl of saliva. For the extraction, 1.5 ml of ethyl acetate was added, and the mixture was vortexed for 1 min. After centrifugation, the supernatant was separated and dried under nitrogen stream at 37–40°C. Dry residue was dissolved with 100 µl of mobile phase, and 20 µl was injected into a Shimadzu LC-6A A Phenomenex® Luna C18 column (5 µm, 100 Å, 150 mm × 4.6 mm), which was used as a reversed stationary phase. The mobile phase was a mixture of 50 mM phosphate buffer and acetonitrile (72:8).

STATISTICAL ANALYSIS

Clinical data from patients were analyzed using non-parametric and unpaired tests (p < 0.05); allelic and genotype relative frequencies were analyzed using the Fisher exact test in Graph Pad Prism software version 4.00 (GraphpadPrisma Software Inc.® San Diego, CA, USA). Hardy–Weinberg equilibrium (HWE) values were derived from chi-square tests, and the association between odds ratios (ORs) and confidence intervals was determined using software available at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.

RESULTS

CLINICAL DATA

Because previous studies suggest that external factors such as gender, age of onset, number of seizures, and other factors influence the response to AED treatment, the selection of a homogeneous population for the study was an important aspect of this work (21, 22). There was no significant difference in male: female frequency between the two groups used in the study. Neither the average age of the patients (10.57 ± 1.56 for patients with good response to AEDs and 10.23 ± 0.78 for patients with ADR; p = 0.42) or the average age of onset of seizures (4.57 ± 1.43 years in patients with good response to AEDs and 4.38 ± 0.81 patients with ADR; p = 0.34) differed significantly. Furthermore, the average seizure-free time in patients with good response to AEDs was 1.9 years, while the average time with seizures in patients with ADR was 5.8 years with a frequency of 63.4 seizures per month. The AEDs VPA, CBZ, LTG, PHT, and LEV were used with relative frequencies of 0.71, 0.14, 0.29, 0.0, and 0.14, respectively, in patients with good response to AEDs and with relative frequencies of 0.59, 0.09, 0.0, 0.18, and 0.23, respectively, in patients with ADR. The most commonly used AED was VPA, but VPA and CBZ were prescribed to both groups (Table 1). The daily dose of VPA (814.3 ± 212.1 mg/day in patients with good response to AEDs and 598.0 ± 129.7 mg/day in patients with ADR; p = 0.206) was similar in the two groups. The two groups showed no significant difference in mean plasma VPA concentrations (35.17 ± 18.04 mg/l patients with good response to AEDs and 31.62 ± 8.03 mg/l in patients with ADR; p = 0.42); however, the average saliva drug concentration was lower in patients with ADR (1.68 ± 0.59 mg/l patients with good response to AEDs and 0.57 ± 0.12 mg/l patients with ADR; p = 0.01).

POLYMORPHISMS IN THE ABCB1 AND ABC22 GENES IN HISPANIC AND MEXICAN POPULATIONS

In this study, chromatograms from amplicons were analyzed to identify expected polymorphisms and to determine the relative frequencies of alleles and genotypes, as described in Table 3. For ABCB1, only the polymorphisms rs2229109, rs1128503, rs28381902, rs2032582, and rs1045642, but not rs9282564, were detected, whereas rs3740066 but not rs2273697, rs8187692, rs17222723, rs7899457, or rs8187710 were found in ABCB2 in our patients, unlike the Hispanic/Mexican populations initially selected by the NCBI GenBank. In addition to these known polymorphisms, we identified rs2214102, rs1128503, rs2235047, and rs2235048 of ABCB1 by sequencing the entire fragment including the exon and parts of the introns.

Another comparison was made between the relative frequencies of the minor allele (MAF) in our population and in the population represented by the NCBI GenBank data. The most significant similarities were found in rs1128503 and rs3740066 in ADR and in rs1045642 and rs2235048 in CTR (Table 3).

An important aspect of genetic alteration is whether a nucleotide change results in a change in an amino acid residue and whether this, in turn, structurally modifies the protein. In
Table 2 | Primers used on ABCB1 and ABCC2 fragments amplification.

| GEN | EXON | Fw Primer | RV Primer | MgCl₂ (mM) | T°h | Size (bp) |
|-----|------|-----------|-----------|-----------|-----|----------|
| ABCB1 | 2 | 5′-AGGTAGTCTGTCACCTCCACGCA-3′ | 5′-GGCTAGTTGGCGCTTATAA-3′ | 1.0 | 57 | 270 |
| | 11 | 5′-ATTCGAAGATGGGCCACAA-3′ | 5′-TCATGCACTCACCCTCTGAT-3′ | 1.0 | 52 | 398 |
| | 12 | 5′-ATTCGAAGATGGGCCACAA-3′ | 5′-TCATGCACTCACCCTCTGAT-3′ | 1.0 | 52 | 398 |
| | 14 | 5′-TTGGGCTGTATGATAGGATCC-3′ | 5′-AAGCCTACGTAGCTTACCTCCA-3′ | 1.5 | 55 | 274 |
| | 21 | 5′-CAGGATCTGAAATGTAGGAA-3′ | 5′-TCCAAGAAGTGGTGGCTA-3′ | 1.75 | 56 | 576 |
| | 26 | 5′-TGTGCTGTGTCGAGTTGATG-3′ | 5′-TGTCGAAACCTTTCCTCCTC-3′ | 1.50 | 62 | 472 |
| ABCC2 | 10 | 5′-TTAGGCTGACCTCATCCTC-3′ | 5′-GCCCCAATCCCATAAGAA-3′ | 1.25 | 56 | 366 |
| | 25 | 5′-CCGGACTGCCTGATCTTCTT-3′ | 5′-ATGGTAATACCCAGGGAA-3′ | 1.0 | 54 | 273 |
| | 28 | 5′-TTCTATGACAGTCCTGGG-3′ | 5′-CATCCAGGCTTCCTTCAT-3′ | 1.25 | 56 | 258 |
| | 29 | 5′-CCCCAAAGATATTTTGTTGGA-3′ | 5′-GCATGTTGCCGAAGATTG-3′ | 1.5 | 57 | 238 |
| | 32 | 5′-GCCTAGACTTGGAGATGCTGC-3′ | 5′-TGGGGCTTCTGCTGATAATT-3′ | 1.5 | 55 | 198 |

The primer design was performed using the web page http://www.yeastgenome.org/cgi-bin/web-primer, T°h were selected by a temperature gradient, and MgCl₂ concentration was selected initially with 2.0 mM and performed gradually until obtained a single sharp band.

Table 2 | Primers used on ABCB1 and ABCC2 fragments amplification.

The relative frequencies of the studied alleles were also compared with their frequencies in the Hispanic and Mexican reference populations reported in the NCBI GenBank (Table 4). In our population, SNP rs2229109 in exon 10 of ABCB1 occurred with a relative frequency of 0.09 and was only present in heterozygous form in the ADR group (Table 4). Although a reference for the Mexican population was not available, we observed that our results showed a twofold higher minor allele frequency with respect to sample s48292345 from the Hispanic population (0.043) in a similar number of individuals (Table 4). The SNPs rs1128503 and rs2032582 in exons 11 and 20, respectively, of the ABCB1 gene showed similar relative frequencies in the CTR (0.71) and ADR (0.82) patient groups; however, there was a difference in the frequencies of homozygotes and heterozygotes in the CTR and ADR groups at both the allelic and the genotypic levels. Furthermore, the SNPs rs2229109 and rs2032582 are of interest due to the possible modifications that they may produce in protein MDR1 (Table 3).

Some other differences observed in this study are worth noting. At SNP rs2032582, the allelic and genotypic distribution in the controlled group was more similar to reported populations in NCBI GenBank than was that of the ADR; in particular, the heterozygous A>T mutation was not found in other populations similar to ours. Furthermore, although allele A of SNP rs2229109 was present at a lower frequency, our population showed an allele frequency more than 2.5-fold greater than the reported MAF (0.045 vs. 0.017).

NEW POLYMORPHISMS OF THE ABCC2 GENE IN MEXICAN EPILEPTIC PEDIATRIC PATIENTS

By sequencing amplicons from exons 28 and 29 of the ABCB1 and ABCC2 genes, we found other single-nucleotide changes (SNCs) that have not been reported in the NCBI GenBank database (Table 2, RefSeqGene NG_011798.1). The SNC located in position 66744T>G adjacent to rs3740066 in exon 28 is present in a homozygous wild-type or heterozygous mutation, allowing the formation of four different triplets: ATC, ATT, AGT, and AGC. The ATC and ATT triplets, which show relative frequencies of 0.82 and 0.68 for triplet ATC and 0.071 and 0.205 for triplet ATT in CTR and ADR, respectively, are not associated with an amino acid change (Ile1324Ile). The AGT and AGC triplets produce an amino acid change (Ile1324Ser, Figure 1A); these occur
Table 3 | Genotype and allelic relative frequencies of SNPs, MAF value, amino acid changes, and OR found in \textit{ABCB1} and \textit{ABCC2} genes.

| Gene     | SNP      | Sample | Allele frequency | Genotype frequency | MAF       | Protein association | Odds ratio |
|----------|----------|--------|------------------|--------------------|-----------|---------------------|------------|
|          |          |        |                  |                    |           | aa, change          | Localization                     |
|          |          |        |                  |                    |           |                     | Allele | Genotype |
|          |          |        |                  |                    |           |                     | Heterozygous | Homozygous |
| \textit{ABCB1} | rs2214102 | CTR | G = 1.000 | G/G = 1.000 | A = 0.040/88 | 5'UTR region | [G] \(\rightarrow\) [A], 2.446 | [GG] \(\rightarrow\) [GA], 2.692 | [GG] \(\rightarrow\) [AA], 0.385 |
|          | ADR      |       | G = 0.971 | G/G = 0.955 | A = 0.029 |                      |                 |
|          |          |        | A = 0.029 | G/A = 0.046 |                   |                 |
| rs229109 | CTR      | G = 1.000 | G/G = 1.000 | A = 0.017/36 | 400; G \(\rightarrow\) A; Ser \(\rightarrow\) Asn | Cytoplasmatic; binding site; Second domain | [G] \(\rightarrow\) [A], 1.706 | [GG] \(\rightarrow\) [GA], 1.829 | [GG] \(\rightarrow\) [AA], 0.366 |
|          | ADR      | G = 0.955 | G/G = 0.909 | A = 0.045 |                   |                 |
|          |          |        | A = 0.045 | G/A = 0.091 |                   |                 |
| rs1128503| CTR      | T = 0.571 | C/T = 0.571 | T = 0.422/919 | 412; T \(\rightarrow\) C; Gly \(\rightarrow\) Gly | Cytoplasmatic; beta chain; second domain | [T] \(\rightarrow\) [C], 1.543 | [TT] \(\rightarrow\) [TC], 1.200 | [TT] \(\rightarrow\) [CC], 3.000 |
|          |          |        | C = 0.429 | T/C = 0.143 |                   |                 |
|          | ADR      | T = 0.455 | C/T = 0.545 | T = 0.182 |                   |                 |
|          |          |        | C = 0.545 | T/C = 0.273 |                   |                 |
| rs2032582| CTR      | G = 0.500 | G/T = 0.429 | A = 0.340/741 | 893; T \(\rightarrow\) A; Ser \(\rightarrow\) Thr | Cytoplasmatic; Alpha-helix chain; third domain | [T] \(\rightarrow\) [A], 2.143 | [TT] \(\rightarrow\) [TA], 2.778 | [TT] \(\rightarrow\) [AA], 0.526 |
|          |          |        | T = 0.500 | G/T = 0.286 |                   |                 |
|          | ADR      | G = 0.523 | G/T = 0.364 | T = 0.286 |                   |                 |
|          |          |        | T = 0.409 | G/T = 0.318 |                   |                 |
|          |          |        | A = 0.068 | T/G = 0.182 |                   |                 |
|          |          |        | A/G = 0.045 | A/T = 0.091 |                   |                 |
| rs1045642| CTR      | T = 0.429 | TT = 0.143 | T = 0.397/864 | 1145; T \(\rightarrow\) Ile \(\rightarrow\) Ile | Cytoplasmatic, fourth domain | [T] \(\rightarrow\) [C], 0.825 | [TT] \(\rightarrow\) [TC], 0.500 | [TT] \(\rightarrow\) [CC], 0.600 |
|          |          |        | C = 0.571 | TC = 0.571 |                   |                 |
|          | ADR      | T = 0.475 | TT = 0.255 | CC = 0.286 |                   |                 |
|          |          |        | C = 0.525 | TC = 0.450 |                   |                 |
|          |          |        | A = 0.068 | CC = 0.300 |                   |                 |
| rs2235047| CTR      | T = 0.857 | TT = 0.714 | G = 0.179/389 | Intron between 25 and 26 exon | [T] \(\rightarrow\) [G], 1.020 | [TT] \(\rightarrow\) [TG], 1.026 | [TT] \(\rightarrow\) [GG], 0.407 |
|          |          |        | G = 0.143 | TG = 0.286 |                   |                 |
|          | ADR      | T = 0.800 | TT = 0.600 | G = 0.400 |                   |                 |
Table 3 | Continued

| Gene   | SNP       | Sample | Allele frequency | Genotype frequency | MAF       | Protein association | Odds ratio |
|--------|-----------|--------|------------------|--------------------|-----------|---------------------|------------|
|        |           |        |                  |                    |           | aa, change          | Localization | Allele | Genotype |
|        |           |        |                  |                    |           |                     | Heterozygous | Homozygous |
| rs2235048 | CTR  | C = 0.429 | CC = 0.143 | C = 0.398/867 | Intron between 25 and 26 exon | [C] ↔ [T], 0.682 | [CC] ↔ [CT], 0.417 | [CC] ↔ [TT], 0.417 |
|        | ADR  | C = 0.525 | CC = 0.300 | T = 0.472 | T/T = 0.286 | [CC] ↔ [CT], 0.417 | [CC] ↔ [TT], 0.417 |
| ABCC2   | 66744 T > G | CTR  | T = 1.000 | T/T = 1.000 | No reported | 1323; T > G; Ile > Ser | Cytoplasmatic region, fourth domain | [T] ↔ [G], 4.038 | [TT] ↔ [TG], 4.1714 | [TT] ↔ [GG], 0.429 |
|         | ADR  | G = 0.110 | T/A = 0.230 | | | | |
| rs3740066 | CTR  | C = 0.928 | C/C = 0.857 | C = 0.304/663 | 1324; C > T; Ile > Ile | Cytoplasmatic region, fourth domain | [C] ↔ [T], 4.875 | [CC] ↔ [CT], 2.769 | [CC] ↔ [TT], 3.370 |
|         | ADR  | C = 0.727 | C/T = 0.519 | T = 0.372 | T/T = 0.196 | | |
| 68049 T > A | CTR  | T = 0.790 | T/T = 0.570 | No reported | 1373; T > A; Leu > His | Cytoplasmatic region, fourth domain | [T] ↔ [A], 0.733 | [TT] ↔ [TA], 0.687 | [TT] ↔ [AA], 0.310 |
|         | ADR  | A = 0.210 | T/A = 0.430 | | | | |
| 67967 C > A | CTR  | C = 0.550 | C/A = 1.000 | No reported | 1342; C > A; Ser > Ser | Cytoplasmatic region, fourth domain | [C] ↔ [A], 0.760 | [CC] ↔ [CA], 0.371 | [CC] ↔ [AA], 0.143 |
|         | ADR  | A = 0.450 | C/A = 0.860 | | | | |
| 68072 C > A | CTR  | C = 0.500 | C/A = 1.000 | No reported | 1381; C > A; Pro > Thr | Cytoplasmatic region, fourth domain | [C] ↔ [A], 0.750 | [CC] ↔ [CA], 0.352 | [CC] ↔ [AA], 0.143 |
|         | ADR  | C = 0.500 | C/A = 1.000 | | | | |
| 68088 G > C | CTR  | G = 0.710 | G/G = 0.710 | No reported | Intron between 29 and 30 | | | | |
|         | ADR  | C = 0.290 | C/G = 0.540 | | | | |

Relative frequencies are presented for the five SNPs reported on NCBI Gene Bank database of ABCB1 and ABCC2 genes among 14 controlled and 44 drug-resistant patients (2n), obtained by direct sequencing. The position indicates the nucleotide change at ABCC2 gene from RefSeqGene NG_011798.1. Amino acid change was obtained from SNP page and its localization from http://www.uniprot.org/ website. Odds ratio (OR) represents the allele risk or mutated using the software on line through the web page http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Bold font: allele OR > 1.0. DR, drug-resistant; CTR, controlled; MAF, Minor Allele Frequency.
Table 4 | Genotype and allelic population frequencies of SNPs found in ABCB1 and ABCC2 genes.

| Gene       | SNP      | NCBI assay ID | Population | Sample (2n) | Allele frequency | Genotype frequency |
|------------|----------|---------------|------------|-------------|------------------|--------------------|
| ABCB1      | rs2235048| ss35072278    | Hispanic   | 44          | T = 0.455        | TT = 0.182         |
|            |          |               |            |             | C = 0.545        | TC = 0.545         |
|            |          | ss48292340    | Hispanic   | 38          | T = 0.553        | TT = 0.369         |
|            |          |               |            |             | C = 0.447        | TC = 0.368         |
|            |          | ss44833502    | Mexican    | 100         | T = 0.540        | TT = 0.260         |
|            |          |               |            |             | C = 0.460        | TC = 0.560         |
|            | rs2235047| ss35072277    | Hispanic   | 44          | T = 0.932        | TT = 0.864         |
|            |          |               |            |             | G = 0.068        | TG = 0.136         |
|            |          | ss48292339    | Hispanic   | 42          | T = 0.952        | TT = 0.905         |
|            |          |               |            |             | G = 0.048        | TG = 0.095         |
|            | rs1045642| ss35072275    | Hispanic   | 42          | T = 0.452        | TT = 0.238         |
|            |          |               |            |             | C = 0.548        | TC = 0.429         |
|            |          | ss48292345    | Hispanic   | 46          | C = 0.540        | TT = 0.180         |
|            |          |               |            |             | T = 0.460        | TC = 0.560         |
|            | rs2229109| ss35072104    | Hispanic   | 44          | G = 0.957        | G/G = 0.913        |
|            |          |               |            |             | A = 0.043        | A/G = 0.087        |
|            |          | ss52073858    | Mexican    | 77          | G = 0.980        | G/G = 0.960        |
|            |          |               |            |             | A = 0.020        | A/G = 0.040        |
|            | rs2229109| ss35072104    | Hispanic   | 44          | G = 1.000        | G/G = 1.000        |
|            |          |               |            |             | A = 0.000        | A/G = 0.000        |
|            |          | ss48292345    | Hispanic   | 46          | G = 0.978        | G/G = 0.957        |
|            |          |               |            |             | A = 0.022        | A/G = 0.043        |
|            | rs1128503| ss35072107    | Hispanic   | 44          | T = 0.545        | C/T = 0.545        |
|            |          |               |            |             | C = 0.455        | T/T = 0.273        |
|            |          | ss48292343    | Hispanic   | 46          | C = 0.609        | C/T = 0.522        |
|            |          |               |            |             | T = 0.391        | C/C = 0.348        |
|            |          | ss52068966    | Mexican    | 77          | C = 0.540        | C/T = 0.560        |
|            |          |               |            |             | T = 0.460        | C/C = 0.260        |
|            | rs2032582| ss12675210    | Hispanic   | 46          | G = 0.565        | G/T = 0.522        |
|            |          |               |            |             | T = 0.392        | G/G = 0.261        |
|            |          |               |            |             | A = 0.043        | T/T = 0.130        |
|            |          |               |            |             | A/G = 0.08        |
|            | ss35072218| ss12675210    | Hispanic   | 44          | G = 0.545        | G/T = 0.636        |
|            |          |               |            |             | T = 0.455        | G/G = 0.227        |
|            |          |               |            |             | T/T = 0.136      |
|            |          |               |            |             | A/G = 0.08        |
|            | rs2032582| ss12675210    | Mexican    | 77          | G = 0.570        | G/T = 0.540        |
|            |          |               |            |             | T = 0.430        | G/G = 0.300        |
|            |          |               |            |             | T/T = 0.160      |
for increased anti-epileptic drug resistance than
ABCB1 polymorphisms
demonstrated a relationship between the
CGC haplotype at SNPs rs1128503, rs2032582, and rs1045642, respectively, and resistance to several AEDs. In another report, Seo et al. (10) demonstrated that Japanese with anti-epileptic
drug-resistant epilepsy showed a tendency to possess the haplotype TTT at SNPs rs1128503, rs2032582, and rs1045642 when CBZ was employed. To enable comparison with those reports, haplotype frequency was calculated in our population. Both haplotypes (CGC and TTT) were found in our population. Within each group, the two haplotypes occurred with similar frequencies (CGC = 0.619, TTT = 0.523 in ADR and CGC = 0.714, TTT = 0.714 in CTR), but both were present at higher frequencies in the CTR group.

For patients who exhibit a mutated allele, OR values can be used to represent relative risk factors among the ADR and CTR patients. The polymorphisms or nucleotide changes, in descending order of risk factor magnitude, are rs2214102 > rs2032582 [T ↔ A] > rs2222109 > rs1128503 > rs2032582 [T ↔ G] > rs2235047 in ABCB1, and rs3740066 > 66744 T > G in ABCC2; relative to heterozygote genotype rs2032582 [T ↔ A] > rs2214102 > rs2222109 > rs2032582 [T ↔ G] > rs1128503 > rs2235047 in ABCB1, and 66744 T > G > rs3740066 in ABCC2; finally, with regard to the homozygote genotype, rs1128503 > rs2032582 [T ↔ G] in ABCB1 and rs3740066 in ABCC2 (Table 3).

Although the number of patients is lower in our work, the results are similar to studies with larger numbers of patients (25, 29, 30), where the lack of association of ABCB1 polymorphisms with anti-epileptic drug resistance (indicated by us as a risk factor) it has been pointed out, including two Indian studies (31, 32) and a meta-analysis (26). In contrast, Taur et al. (33) and Siddiqui et al. (34) reported association with anti-epileptic drug resistance. On the other hand, we find that the ABCB2 is a greater risk factor for increased anti-epileptic drug resistance than ABCB1, although

A Table 3

DISCUSSION

The pediatric epilepsy patients admitted to the Neurology Service, Hospital of Pediatrics, National Medical Center, Century XXI, were referred from family clinics and general hospitals for inadequate control of epileptic seizures. In most cases, the patients received dosage adjustments or changes in drug regimen, drug monitoring, and electroencephalographic studies and were followed closely for adequate control of their seizures. However, some patients continued to interictal epileptiform discharges on EEG and/or the occurrence of seizures, and some gradually deteriorated. The results obtained with a small group of patients who did not respond to at least three different drug regimens but were followed for 4.7 ± 3.8 (CI = 1–14) years are presented in this work.

Fagioli et al. (23) suggested that the quantitation of drugs in saliva can be used to identify drug-resistant patients. The hypothesis presented by these authors is based on the drug concentration circulating in free plasma, which irrigates the glandular capillary tissue, resulting in equilibrium with the aqueous spaces. Considering our results with respect to this hypothesis, we found a lower concentration of free VPA in drug-resistant patients, suggesting a possible deficiency in drug transport in these patients.

The overexpression of P-gp and MRP2 in resected tissue from patients who have undergone surgery for epilepsy suggests that this phenomenon may be conditional upon the presence of polymorphisms in the genes ABCB1 and ABCB2 and not simply to exposure to xenobiotics that recognize these transporter proteins. However, the association between polymorphisms of the ABCB1 and ABCB2 genes and anti-epileptic drug-resistant epilepsy is controversial; SNPs rs1128503 (C1236T), rs2032582 (G2677T/A), and especially rs1045642 (C3435T) in the ABCB1 gene have not shown a clear relationship to anti-epileptic drug-resistant epilepsy from different populations or ethnic groups (13, 24–27). This may be because, as has been reported, SNP rs1045642 is more relevant as a haplotype with rs1128503 and rs2032582. Zimpichet et al. (28), studying European patients with temporal lobe epilepsy, demonstrated a relationship between the CGC haplotype at SNPs rs1128503, rs2032582, and rs1045642, respectively, and resistance to several AEDs. In another report, Seo et al. (10) demonstrated that Japanese with anti-epileptic drug-resistant epilepsy showed a tendency to possess the haplotype TTT at SNPs rs1128503, rs2032582, and rs1045642 when CBZ was employed. To enable comparison with those reports, haplotype frequency was calculated in our population. Both haplotypes (CGC and TTT) were found in our population. Within each group, the two haplotypes occurred with similar frequencies (CGC = 0.619, TTT = 0.523 in ADR and CGC = 0.714, TTT = 0.714 in CTR), but both were present at higher frequencies in the CTR group.

For patients who exhibit a mutated allele, OR values can be used to represent relative risk factors among the ADR and CTR patients. The polymorphisms or nucleotide changes, in descending order of risk factor magnitude, are rs2214102 > rs2032582 [T ↔ A] > rs2222109 > rs1128503 > rs2032582 [T ↔ G] > rs2235047 in ABCB1, and rs3740066 > 66744 T > G in ABCC2; relative to heterozygote genotype rs2032582 [T ↔ A] > rs2214102 > rs2222109 > rs2032582 [T ↔ G] > rs1128503 > rs2235047 in ABCB1, and 66744 T > G > rs3740066 in ABCC2; finally, with regard to the homozygote genotype, rs1128503 > rs2032582 [T ↔ G] in ABCB1 and rs3740066 in ABCC2 (Table 3).

Although the number of patients is lower in our work, the results are similar to studies with larger numbers of patients (25, 29, 30), where the lack of association of ABCB1 polymorphisms with anti-epileptic drug resistance (indicated by us as a risk factor) it has been pointed out, including two Indian studies (31, 32) and a meta-analysis (26). In contrast, Taur et al. (33) and Siddiqui et al. (34) reported association with anti-epileptic drug resistance. On the other hand, we find that the ABCB2 is a greater risk factor for increased anti-epileptic drug resistance than ABCB1, although
FIGURE 1 | Chromatograms of single-nucleotide changes found in the ABCC2 gene from Mexican pediatric patients with epilepsy. (A) The 66744 T > G change is located in exon 28. (B) The 67967 C > A change is located in exon 29. (C) The 68049 T > A change is located in exon 29. (D) The 68072 C > A change is located in exon 29. (E) The 68088 G > C change is located in intron 29. The position indicates the nucleotide change in the ABCC2 gene (RefSeqGene NG_011798.1).
in previous studies, we only share the SNP rs3740066, not representing a major risk factor as the high activity promoter variant c-24C > T; these data suggest that ABC2 polymorphism may affect the response to AEDs.

This study employed a different strategy, rigorously selecting pediatric patients with ADR and patients with good seizure control to decrease the potential influence of confounding variables associated with the disease, to develop a study utilizing a non-inferential exploratory search based on the polymorphisms already reported and on unreported new characteristics of the Mexican population. Because our population has been little studied, this will allow us to conduct association studies with new SNPs and AEDs used to treat different forms of epilepsy. To avoid sequencing entire genes, we selected exons containing polymorphisms that have been previously reported in Mexican and Hispanic populations, including the P-gp and MR2 proteins, which are associated with drug resistance. The most important outcome of this study was the identification of five new changes in the ABC2; these are 66744T > G, 67967C > A, 68072C > A, 68049C > A, and G68088C. The nucleotide change 66744T > G was found only in ADR, and the risk factor associated with it was one of the highest found in the study. Moreover, the genetic variability in SNP rs2032582 in ADR was different and unexpected vs ADR, and the risk factor associated with it was one of the highest found in the study. Moreover, the genetic variability in SNP rs2032582 in ADR was different and unexpected.
30. Szoeke C, Sills GJ, Kwan P, Petrovski S, Newton M, Hitiris N, et al. Multidrug-resistance genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from International Pharmacogenetic Cohorts. *Epilepsia* (2009) 50:1689–96. doi:10.1111/j.1528-1167.2009.02059.x

31. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. *Epilepsy Behav* (2009) 14:78–82. doi:10.1016/j.yebeh.2008.08.019

32. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. *Drug Metab Pharmacokinet* (2009) 24:255–60. doi:10.2133/dmpk.24.255

33. Taur SR, Kulkarni NB, Gandhe PP, Thelma BK, Ravat SH, Gogtay N, et al. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs. *J Postgrad Med* (2014) 60(3):265–9. doi:10.4103/0022-3859.138739

34. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. *N Engl J Med* (2003) 348:1442–8. doi:10.1056/NEJMoat014886

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 24 July 2014; accepted: 09 September 2014; published online: 09 October 2014.

Citation: Escalante-Santiago D, Feria-Romero IA, Ribas-Aparicio RM, Rayo-Mares D, Fagiolino P, Vázquez M, Escamilla-Núñez C, Grijalva-Otero I, López-García MA and Orozco-Suárez S (2014) MDR-1 and MRP2 gene polymorphisms in Mexican epileptic pediatric patients with complex partial seizures. *Front. Neurol.* 5:184. doi: 10.3389/fneur.2014.00184

This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology. Copyright © 2014 Escalante-Santiago, Feria-Romero, Ribas-Aparicio, Rayo-Mares, Fagiolino, Vázquez, Escamilla-Núñez, Grijalva-Otero, López-García and Orozco-Suárez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.